Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
Roberta Alfieri(University of Parma), Pier Giorgio Petronini(University of Parma)
Cited by 46
Related Papers
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
|Journal of Experimental & Clinical Cancer Research|2017|89
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
|Journal of Experimental & Clinical Cancer Research|2019|70
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
|Molecular Cancer|2014|67